Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications

Abstract

Recent advances in nanotechnology have enabled significant developments in health through innovative drug delivery systems. Nanostructured lipid carriers (NLCs) have emerged as a key technology in this field, offering enhanced drug stability, improved loading capacity, and reduced drug leakage compared to traditional solid lipid nanoparticles (SLNs). NLCs, such as ARM-NLC and PIO-loaded NLCs are specifically designed to optimize drug delivery and efficacy. Unlike other nanocarriers, NLCs provide controlled release and targeted delivery, making them highly effective for treating a range of diseases. Their applications include the treatment of skin cancer, Parkinson's disease, Alzheimer's disease, and breast cancer. The use of surface-engineered nanolayer coatings in NLCs has demonstrated significant improvements in targeting and delivering medications and bioactive substances to infection sites. Both in vitro and in vivo studies have shown promising results regarding the safety and efficacy of these NLC-based drug delivery systems.

Keywords

Nanostructured lipid carriers / Skin cancer / Parkinson's disease / Alzheimer's disease

References

[1] Alshawwa SZ , Kassem AA , Farid RM , Mostafa SK , Labib GS . Nanocarrier drug delivery systems:characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022; 14 (4): 883.

[2] Kaushik N , Borkar SB , Nandanwar SK , Panda PK , Choi EH , Kaushik NK . Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms. J Nanobiotechnol. 2022; 20 (1): 152.

[3] Gaba B , Khan T , Haider MF , et al. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson's disease model. BioMed Res Int. 2019; 2019.

[4] Ajalli N , Pourmadadi M , Yazdian F , Rashedi H , Navaei-Nigjeh M , Díez-Pascual AM . Chitosan/Gamma-Alumina/Fe3O4@5-FU nanostructures as promising nanocarriers:physiochemical characterization and toxicity activity. Molecules. 2022; 27 (17): 5369.

[5] Ahmad I , Khan MFA , Rahdar A , et al. Design and evaluation of pH sensitive PEGprotamine nanocomplex of doxorubicin for treatment of breast cancer. Polymers. 2022; 14 (12): 2403.

[6] Al-Joufi FA , Setia A , Salem-Bekhit MM , et al. Molecular pathogenesis of colorectal cancer with an emphasis on recent advances in biomarkers, as well as nanotechnology-based diagnostic and therapeutic approaches. Nanomaterials. 2022; 12 (1): 169.

[7] Alshareeda AT , Khatijah MN , Al-Sowayan BS . Nanotechnology:a revolutionary approach to prevent breast cancer recurrence. Asian J Surg. 2023; 46 (1): 13- 17.

[8] Byeon JC , Ahn JB , Jang WS , Lee SE , Choi JS , Park JS . Recent formulation approaches to oral delivery of herbal medicines. Journal of pharmaceutical investigation. 2019; 49: 17- 26.

[9] Chamundeeswari M , Jeslin J , Verma ML . Nanocarriers for drug delivery applications. Environ Chem Lett. 2019; 17: 849- 865.

[10] Pontes JF , Grenha A . Multifunctional nanocarriers for lung drug delivery. Nanomaterials. 2020; 10 (2): 183.

[11] Adnan M , Afzal O , Altamimi AS , Alamri MA , Haider T , Haider MF . Development and optimization of transethosomal gel of apigenin for topical delivery:in-vitro, exvivo and cell line assessment. Int J Pharm. 2023; 631: 122506.

[12] Jahanshahi M , Babaei Z . Protein nanoparticle:a unique system as drug delivery vehicles. Afr J Biotechnol. 2008; 7 (25).

[13] Alexis F , Pridgen E , Molnar LK , Farokhzad OC . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5 (4): 505- 515.

[14] Alam T , Khan S , Gaba B , Haider MF , Baboota S , Ali J . Nanocarriers as treatment modalities for hypertension. Drug Deliv. 2017; 24 (1): 358- 369.

[15] Ahmed KS , Hussein SA , Ali AH , Korma SA , Lipeng Q , Jinghua C . Liposome:composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019; 27 (7): 742- 761.

[16] Khan N , Shah FA , Rana I , et al. Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity. Int J Pharm. 2020; 577: 119033.

[17] Leyva-Gómez G , Piñón-Segundo E , Mendoza-Muñoz N , Zambrano-Zaragoza ML , Mendoza-Elvira S , Quintanar-Guerrero D . Approaches in polymeric nanoparticles for vaginal drug delivery:a review of the state of the art. Int J Mol Sci. 2018; 19 (6): 1549.

[18] Kumari A , Yadav SK , Yadav SC . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and surfaces B:biointerfaces. 2010; 75 (1): 1- 18.

[19] Nagavarma BVN , Yadav HK , Ayaz AVLS , Vasudha LS , Shivakumar HG . Different techniques for preparation of polymeric nanoparticles-a review. Asian J Pharmaceut Clin Res. 2012; 5 (3): 16- 23.

[20] Biswas S , Kumari P , Lakhani PM , Ghosh B . Recent advances in polymeric micelles for anti-cancer drug delivery. Eur J Pharmaceut Sci. 2016; 83: 184- 202.

[21] Chamundeeswari M , Jeslin J , Verma ML . Nanocarriers for drug delivery applications. Environ Chem Lett. 2019; 17: 849- 865.

[22] Alam T , Khan S , Gaba B , Haider MF , Baboota S , Ali J . Adaptation of quality by design-based development of isradipine nanostructured-lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J Pharmaceut Sci. 2018; 107 (11): 2914- 2926.

[23] Hua S . Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol. 2015; 6: 219.

[24] Ahmad MA , Kareem O , Khushtar M , et al. Neuroinflammation:a potential risk for dementia. Int J Mol Sci. 2022; 23 (2): 616.

[25] Jain V , Kumar H , Chand P , Jain S , S P . Lipid-based nanocarriers as drug delivery system and its applications. Nanopharmaceutical advanced delivery systems. 2021: 1- 29.

[26] Haider MF , Kanoujia J , Tripathi CB , Arya M , Kaithwas G , Saraf SA . Pioglitazone loaded vesicular carriers for anti-diabetic activity:development and optimization as per central composite design. Journal of Pharmaceutical Sciences and Pharmacology. 2015; 2 (1): 11- 20.

[27] Chacko IA , Ghate VM , Dsouza L , Lewis SA . Lipid vesicles:a versatile drug delivery platform for dermal and transdermal applications. Colloids Surf B Biointerfaces. 2020; 195: 111262.

[28] Goyal N , Thatai P , Sapra B . Skin cancer:symptoms, mechanistic pathways and treatment rationale for therapeutic delivery. Ther Deliv. 2017; 8 (5): 265- 287.

[29] Filipczak N , Pan J , Yalamarty SSK , Torchilin VP . Recent advancements in liposome technology. Adv Drug Deliv Rev. 2020; 156: 4- 22.

[30] Thabet Y , Elsabahy M , Eissa NG . Methods for preparation of niosomes:a focus on thin-film hydration method. Methods. 2022; 199: 9- 15.

[31] Chen S , Hanning S , Falconer J , Locke M , Wen J . Recent advances in non-ionic surfactant vesicles (niosomes):fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm. 2019; 144: 18- 39.

[32] Sadeghi-Ghadi Z , Ebrahimnejad P , Talebpour Amiri F , Nokhodchi A . Improved oral delivery of quercetin with hyaluronic acid containing niosomes as a promising formulation. J Drug Target. 2021; 29 (2): 225- 234.

[33] Santos AC , Rodrigues D , Sequeira JA , et al. Nanotechnological breakthroughs in the development of topical phytocompounds-based formulations. Int J Pharm. 2019; 572: 118787.

[34] Fernández-García R , Lalatsa A , Statts L , Bolás-Fernández F , Ballesteros MP , Serrano DR . Transferosomes as nanocarriers for drugs across the skin:quality by design from lab to industrial scale. Int J Pharm. 2020; 573: 118817.

[35] Moawad FA , Ali AA , Salem HF . Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl:preparation, in vitro and in vivo performance. Drug Deliv. 2017; 24 (1): 252- 260.

[36] Pathan IB , Jaware BP , Shelke S , Ambekar W . Curcumin loaded ethosomes for transdermal application:formulation, optimization, in-vitro and in-vivo study. J Drug Deliv Sci Technol. 2018; 44: 49- 57.

[37] Mahmood S , Mandal UK , Chatterjee B . Transdermal delivery of raloxifene HCl via ethosomal system:formulation, advanced characterizations and pharmacokinetic evaluation. Int J Pharm. 2018; 542 (1-2): 36- 46.

[38] Chauhan N , Vasava P , Khan SL , et al. Ethosomes:a novel drug carrier. Annals of Medicine and Surgery. 2022: 104595.

[39] Ainbinder D , Touitou E . Testosterone ethosomes for enhanced transdermal delivery. Drug Deliv. 2005; 12 (5): 297- 303.

[40] Haider M , Abdin SM , Kamal L , Orive G . Nanostructured lipid carriers for delivery of chemotherapeutics:a review. Pharmaceutics. 2020; 12 (3): 288.

[41] Duan Y , Dhar A , Patel C , et al. A brief review on solid lipid nanoparticles:Part and parcel of contemporary drug delivery systems. RSC Adv. 2020; 10 (45): 26777- 26791.

[42] Geszke-Moritz M , Moritz M . Solid lipid nanoparticles as attractive drug vehicles:composition, properties and therapeutic strategies. Mater Sci Eng C. 2016; 68: 982- 994.

[43] Kaur H , Kesharwani P . Advanced nanomedicine approaches applied for treatment of skin carcinoma. J Contr Release. 2021; 337: 589- 611.

[44] Srivastava S , Haider MF , Ahmad A , Ahmad U , Arif M , Ali A . Exploring nanoemulsions for prostate cancer therapy. Drug Research. 2021; 71 (8): 417- 428.

[45] Sala M , Diab R , Elaissari A , Fessi H . Lipid nanocarriers as skin drug delivery systems:properties, mechanisms of skin interactions and medical applications. Int J Pharm. 2018; 535 (1-2): 1- 17.

[46] Rajinikanth PS , Chellian J . Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomed. 2016: 5067- 5077.

[47] Tiwari S , Mistry P , Patel V . SLNs based on co-processed lipids for topical delivery of terbinafine hydrochloride. J Pharm Drug Dev. 2014; 1 (6): 604.

[48] Dhiman N , Awasthi R , Sharma B , Kharkwal H , Kulkarni GT . Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021; 9: 580118.

[49] Ghosn Y , Kamareddine MH , Tawk A , et al. Inorganic nanoparticles as drug delivery systems and their potential role in the treatment of chronic myelogenous leukaemia. Technol Cancer Res Treat. 2019; 18: 1533033819853241.

[50] Shi Z , Zhou Y , Fan T , Lin Y , Zhang H , Mei L . Inorganic nano-carriers based smart drug delivery systems for tumor therapy. Smart Materials in Medicine. 2020; 1: 32- 47.

[51] Lin N , Verma D , Saini N , et al. Antiviral nanoparticles for sanitizing surfaces:a roadmap to self-sterilizing against COVID-19. Nano Today. 2021; 40: 101267.

[52] Cai W , Gao T , Hong H , Sun J . Applications of Gold Nanoparticles in Cancer Nanotechnology. Nanotechnology, Science and Applications. 2008: 17- 32.

[53] Mendes R , Fernandes AR , Baptista PV . Gold nanoparticle approach to the selective delivery of gene silencing in cancer-the case for combined delivery? Genes. 2017; 8 (3): 94.

[54] Kalimuthu K , Cha BS , Kim S , Park KS . Eco-friendly synthesis and biomedical applications of gold nanoparticles:a review. Microchem J. 2020; 152: 104296.

[55] Hammami I , Alabdallah NM . Gold nanoparticles:synthesis properties and applications. J King Saud Univ Sci. 2021; 33 (7): 101560.

[56] Meena J , Gupta A , Ahuja R , Singh M , Bhaskar S , Panda AK . Inorganic nanoparticles for natural product delivery:a review. Environ Chem Lett. 2020; 18: 2107- 2118.

[57] Savla R , Garbuzenko OB , Chen S , Rodriguez-Rodriguez L , Minko T . Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy. Pharmaceut Res. 2014; 31: 3487- 3502.

[58] Dani RK , Schumann C , Taratula O , Taratula O . Temperature-tunable iron oxide nanoparticles for remote-controlled drug release. AAPS PharmSciTech. 2014; 15: 963- 972.

[59] Kaur P , Singh KJ , Thakur S , Singh P , Bajwa BS . Investigation of bismuth borate glass system modified with barium for structural and gamma-ray shielding properties. Spectrochim Acta Mol Biomol Spectrosc. 2019; 206: 367- 377.

[60] Jha A , Nikam AN , Kulkarni S , et al. Biomimetic nanoarchitecturing:a disguised attack on cancer cells. J Contr Release. 2021; 329: 413- 433.

[61] Madani F , Lindberg S , Langel Ü , Futaki S , Gräslund A . Mechanisms of cellular uptake of cell-penetrating peptides. Journal of biophysics. 2011; 2011.

[62] Rahamathulla M , Bhosale RR , Osmani RA , et al. Carbon nanotubes:current perspectives on diverse applications in targeted drug delivery and therapies. Materials. 2021; 14 (21): 6707.

[63] Haider MF , Khan S , Gaba B , et al. Optimization of rivastigmine nanoemulsion for enhanced brain delivery:in-vivo and toxicity evaluation. J Mol Liq. 2018; 255: 384- 396.

[64] Kwon S , Singh RK , Perez RA , Abou Neel EA , Kim HW , Chrzanowski W . Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng. 2013; 4: 2041731413503357.

[65] Chen H , Zhen Z , Tang W , et al. Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery. Theranostics. 2013; 3 (9): 650.

[66] Wang J , Li B , Qiu L , Qiao X , Yang H . Dendrimer-based drug delivery systems:history, challenges, and latest developments. J Biol Eng. 2022; 16 (1): 18.

[67] Munir M , Hanif M , Ranjha NM . Dendrimers and their applications:a review article. Pakistan J Pharmaceut Res. 2016; 2 (1): 55- 66.

[68] Chis AA , Dobrea C , Morgovan C , et al. Applications and limitations of dendrimers in biomedicine. Molecules. 2020; 25 (17): 3982.

[69] Song C , Shen M , Rodrigues J , Mignani S , Majoral JP , Shi X . Superstructured poly (amidoamine) dendrimer-based nanoconstructs as platforms for cancer nanomedicine:a concise review. Coord Chem Rev. 2020; 421: 213463.

[70] Xiong Z , Shen M , Shi X . Dendrimer-based strategies for cancer therapy:recent advances and future perspectives. Sci China Mater. 2018; 61 (11): 1387- 1403.

[71] Deshmukh AS , Chauhan PN , Noolvi MN , et al. Polymeric micelles:basic research to clinical practice. Int J Pharm. 2017; 532 (1): 249- 268.

[72] Almeida M , Magalhaes M , Veiga F , Figueiras A . Poloxamers, poloxamines and polymeric micelles:definition, structure and therapeutic applications in cancer. J Polym Res. 2018; 25: 1- 14.

[73] Majumder N , G Das N , Das SK . Polymeric micelles for anticancer drug delivery. Ther Deliv. 2020; 11 (10): 613- 635.

[74] Kim D , Gao ZG , Lee ES , Bae YH . In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm. 2009; 6 (5): 1353- 1362.

[75] Wan X , Min Y , Bludau H , et al. Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer. ACS Nano. 2018; 12 (3): 2426- 2439.

[76] Viegas C , Patrício AB , Prata JM , Nadhman A , Chintamaneni PK , Fonte P . Solid lipid nanoparticles vs. nanostructured lipid carriers:a comparative review. Pharmaceutics. 2023; 15 (6): 1593.

[77] Adnan M , Haider MF , Naseem N , Haider T . Transethosomes:a promising challenge for topical delivery short title:transethosomes for topical delivery. Drug Research. 2023; 73 (4): 200- 212.

[78] Mahor AK , Singh PP , Gupta R , et al. Nanostructured lipid carriers for improved delivery of therapeutics via the oral route. Journal of Nanotechnology. 2023; 2023: 1- 35.

[79] Khosa A , Reddi S , Saha RN . Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018; 103: 598- 613.

[80] Gordillo-Galeano A , Mora-Huertas CE . Solid lipid nanoparticles and nanostructured lipid carriers:a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 2018; 133: 285- 308.

[81] Sharma A , Baldi A . Nanostructured lipid carriers:a review. Journal of Developing Drugs. 2018; 7 (2): 1- 15.

[82] Jaiswal P , Gidwani B , Vyas A . Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells, Nanomed Biotechnol. 2016; 44 (1): 27- 40.

[83] Balguri SP , Adelli GR , Majumdar S . Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016; 109: 224- 235.

[84] Iqbal MA , Md S , Sahni JK , Baboota S , Dang S , Ali J . Nanostructured lipid carriers system:recent advances in drug delivery. J Drug Target. 2012; 20 (10): 813- 830.

[85] Hirlekar R , Patil E , Bhairy S . Solid nanostructured lipid carriers loaded with silymarin for oral delivery:formulation development and evaluation. Curr. Trends Pharm. Pharm. Chem. 2021; 3: 56- 67.

[86] Imran M , Iqubal MK , Imtiyaz K , et al. Topical nanostructured lipid carrier gel of quercetin and resveratrol:formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer. Int J Pharm. 2020; 587: 119705.

[87] Adnan M , Akhter MH , Afzal O , et al. Exploring nanocarriers as treatment modalities for skin cancer. Molecules. 2023; 28 (15): 5905.

[88] Haider M , Abdin SM , Kamal L , Orive G . Nanostructured lipid carriers for delivery of chemotherapeutics:a review. Pharmaceutics. 2020; 12 (3): 288.

[89] Tamjidi F , Shahedi M , Varshosaz J , Nasirpour A . Nanostructured lipid carriers (NLC):a potential delivery system for bioactive food molecules. Innovat Food Sci Emerg Technol. 2013; 19: 29- 43.

[90] Naseri N , Valizadeh H , Zakeri-Milani P . Solid lipid nanoparticles and nanostructured lipid carriers:structure, preparation and application. Adv Pharmaceut Bull. 2015; 5 (3): 305.

[91] Martins S , Tho I , Souto E , Ferreira D , Brandl M . Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles. Eur J Pharmaceut Sci. 2012; 45 (5): 613- 623.

[92] Gaba B , Fazil M , Khan S , Ali A , Baboota S , Ali J . Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ. 2015; 53 (2): 147- 159.

[93] Vivek K , Reddy H , Murthy RS . Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2007; 8: 16- 24.

[94] Lasoń E , Sikora E , Ogonowski J . Influence of process parameters on properties of Nanostructured Lipid Carriers (NLC) formulation. Acta Biochim Pol. 2013; 60 (4).

[95] Shah R , Eldridge D , Palombo E , Harding I . Lipid Nanoparticles:Production, Characterization and Stability. vol. 1. New York, NY, USA:Springer International Publishing; 2015: 23- 43.

[96] Leonardi A , Bucolo C , Romano GL , et al. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int J Pharm. 2014; 470 (1-2): 133- 140.

[97] Khan Z , Haider MF , Naseem N , Siddiqui MA , Ahmad U , Khan MM . Nanocarrier for the treatment of liver cancer. J Pharmaceut Sci Res. 2022; 14 (11): 944- 957.

[98] Rosenblatt KM , Bunjes H . Poly (vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the α-modification. Mol Pharm. 2009; 6 (1): 105- 120.

[99] Hu FQ , Hong Y , Yuan H . Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm. 2004; 273 (1-2): 29- 35.

[100] Khan A , Naquvi KJ , Haider MF , Khan MA . Quality by design-newer technique for pharmaceutical product development. Intelligent Pharmacy. 2023.

[101] Fatima A , Nasim N , Haider MF , et al. A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer. Intelligent Pharmacy. 2024; 2: 415- 426.

[102] Puglia C , Blasi P , Rizza L , et al. Lipid nanoparticles for prolonged topical delivery:an in vitro and in vivo investigation. Int J Pharm. 2008; 357 (1-2): 295- 304.

[103] Agrawal M , Saraf S , Saraf S , et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Contr Release. 2020; 321: 372- 415.

[104] Sahoo PK , Neha SL , Pannu A . An overview of second-generation nanoparticles-nano-structure lipid carrier drug delivery system. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN). 2020; 13 (6): 5181- 5189.

[105] Chauhan I , Yasir M , Verma M , Singh AP . Nanostructured lipid carriers:a groundbreaking approach for transdermal drug delivery. Adv Pharmaceut Bull. 2020; 10 (2): 150.

[106] Carmona-Ribeiro AM . Biomimetic nanoparticles:preparation, characterization and biomedical applications. Int J Nanomed. 2010: 249- 259.

[107] Apostolou M , Assi S , Fatokun AA , Khan I . The effects of solid and liquid lipids on the physicochemical properties of nanostructured lipid carriers. J Pharmaceut Sci. 2021; 110 (8): 2859- 2872.

[108] Battaglia L , Gallarate M . Lipid nanoparticles:state of the art, new preparation methods and challenges in drug delivery. Expet Opin Drug Deliv. 2012; 9 (5): 497- 508.

[109] Shidhaye SS , Vaidya R , Sutar S , Patwardhan A , Kadam VJ . Solid lipid nanoparticles and nanostructured lipid carriers-innovative generations of solid lipid carriers. Curr Drug Deliv. 2008; 5 (4): 324- 331.

[110] Radtke M , Müller RH . Nanostructured lipid drug carriers. N Drugs. 2001; 2: 48- 52.

[111] Westesen K , Bunjes H , Koch MHJ . Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Contr Release. 1997; 48 (2-3): 223- 236.

[112] Jafar GAR , Abdassah MAR , Rusdiana TAO , Khairunisa RIZKI . Development and characterization of precirol ato 88 base in nanostructured lipid carriers (Nlc) formulation with the probe sonication method. Int J Appl Pharm. 2021; 13: 43- 46.

[113] Sadiah S , Anwar E , Djufri M , Cahyaningsih U . Preparation and characteristics of nanostructured lipid carrier (NLC) loaded red ginger extract using high pressure homogenizer method. J Pharmaceut Sci Res. 2017; 9 (10): 1889- 1893.

[114] Wirawan W , Raharjo S , Supriyadi S . Formulation and characteristics of nanostuctured lipid carrier (NLC) red palm oil (RPO) prepared by high-pressure homogenization and its applications in orange juice. Indonesian Food and Nutrition Progress. 2022; 19 (1): 31- 40.

[115] Pinheiro M , Ribeiro R , Vieira A , Andrade F , Reis S . Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Des Dev Ther. 2016: 2467- 2475.

[116] Agrawal M , Saraf S , Pradhan M , Patel RJ , Singhvi G , Alexander A . Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. Biomed Pharmacother. 2021; 141: 111919.

[117] Gundogdu E , Demir ES , Ekinci M , et al. An innovative formulation based on nanostructured lipid carriers for imatinib delivery:pre-formulation, cellular uptake and cytotoxicity studies. Nanomaterials. 2022; 12 (2): 250.

[118] Naseem N , Kushwaha P , Haider F . Leveraging nanostructured lipid carriers to enhance targeted delivery and efficacy in breast cancer therapy:a comprehensive review. N Schmied Arch Pharmacol. 2024: 1- 20.

[119] Dai W , Zhang D , Duan C , et al. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul. 2010; 27 (3): 234- 241.

[120] Aldawsari MF , Kamal MA , Balaha MF , et al. Optimized Ribociclib nanostructured lipid carrier for the amelioration of skin cancer:inferences from ex-vivo skin permeation and dermatokinetic studies. Saudi Pharmaceut J. 2024: 101984.

[121] Sartaj A , Biswas L , Verma AK , Sahoo PK , Baboota S , Ali J . Ribociclib nanostructured lipid carrier aimed for breast cancer:formulation optimization, attenuating in vitro specification, and in vivo scrutinization. BioMed Res Int. 2022; 2022.

[122] Aslam M , Aqil M , Ahad A , Najmi AK , Sultana Y , Ali A . Application of Box-Behnken design for preparation of glibenclamide loaded lipid based nanoparticles:optimization, in vitro skin permeation, drug release and in vivo pharmacokinetic study. J Mol Liq. 2016; 219: 897- 908.

[123] Rahman A , Haider F . A comprehensive review on glucocorticoids induced osteoporosis:a medication caused disease. Steroids. 2024: 109440.

[124] Joshi MD , Prabhu RH , Patravale VB . Fabrication of nanostructured lipid carriers (NLC)-based gels from microemulsion template for delivery through skin. Basic Protocols. Pharm Nanotechnol. 2019: 279- 292.

[125] Jain K , Sood S , Gowthamarajan K . Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv. 2015; 22 (7): 940- 954.

[126] Jojo GM , Kuppusamy G , De A , Karri VNR . Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer's disease using Box-Behnken design. Drug Dev Ind Pharm. 2019; 45 (7): 1061- 1072.

[127] Behbahani ES , Ghaedi M , Abbaspour M , Rostamizadeh K , Dashtian K . Curcumin loaded nanostructured lipid carriers:in vitro digestion and release studies. Polyhedron. 2019; 164: 113- 122.

[128] Rahman A , Haider MDF , Naseem N , Rahman N . Solubility of drugs, their enhancement, factors affecting and their limitations:a review. Int J Pharmaceut Sci Rev Res. 2023; 79: 78- 94.

[129] Emami J , Rezazadeh M , Varshosaz J . Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel:a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater. 2012; 2012, 3- 3.

[130] Elianarni D , Raharjo S , Supriyadi S . Formulation and characteristics of red palm oil nanostractured lipid carriers prepared by microemulsion method and its application in drinking yoghurt. Indonesian Food and Nutrition Progress. 2022; 19 (1): 1- 8.

[131] Orthaber K , Pristovnik M , Skok K , Perić B , Maver U . Skin cancer and its treatment:novel treatment approaches with emphasis on nanotechnology. J Nanomater. 2017; 2017.

[132] Goyal N , Thatai P , Sapra B . Skin cancer:symptoms, mechanistic pathways and treatment rationale for therapeutic delivery. Ther Deliv. 2017; 8 (5): 265- 287.

[133] Pavri SN , Clune J , Ariyan S , Narayan D . Malignant melanoma:beyond the basics. Plast Reconstr Surg. 2016; 138 (2): 330e- 340e.

[134] Ruan R , Chen M , Sun S , et al. Topical and targeted delivery of siRNAs to melanoma cells using a fusion peptide carrier. Sci Rep. 2016; 6 (1): 29159.

[135] Iqubal MK , Iqubal A , Imtiyaz K , et al. Combinatorial lipid-nanosystem for dermal delivery of 5-fluorouracil and resveratrol against skin cancer:delineation of improved dermatokinetics and epidermal drug deposition enhancement analysis. Eur J Pharm Biopharm. 2021; 163: 223- 239.

[136] de Moura LD , Ribeiro LN , de Carvalho FV , et al. Docetaxel and lidocaine co-loaded (NLC-in-hydrogel) hybrid system designed for the treatment of melanoma. Pharmaceutics. 2021; 13 (10): 1552.

[137] Ven^ancio JH , Andrade LM , Esteves NLS , et al. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers. J Pharm Pharmacol. 2017; 69 (10): 1318- 1326.

[138] Carmo Carreiras M , Mendes E , Jesus Perry M , Paula Francisco A , Marco-Contelles J . The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem. 2013; 13 (15): 1745- 1770.

[139] Jahn H . Memory loss in Alzheimer's disease. Dialogues Clin Neurosci. 2013; 15 (4): 445- 454.

[140] Kales HC , Gitlin LN , Lyketsos CG . Assessment and management of behavioral and psychological symptoms of dementia. Bmj. 2015; 350.

[141] Hardy J . The amyloid hypothesis for Alzheimer's disease:a critical reappraisal. J Neurochem. 2009; 110 (4): 1129- 1134.

[142] Ali MH , Alam O , Ali A , et al. Donepezil and Embelin loaded Nanostructured lipid carriers for direct brain delivery as an intervention for Alzheimer's disease:formulation design, Optimization and Evaluation. J Cluster Sci. 2023: 1- 24.

[143] Sadegh Malvajerd S , Izadi Z , Azadi A , et al. Neuroprotective potential of curcuminloaded nanostructured lipid carrier in an animal model of Alzheimer's disease:behavioral and biochemical evidence. J Alzheim Dis. 2019; 69 (3): 671- 686.

[144] Shehata MK , Ismail AA , Kamel MA . Nose to brain delivery of astaxanthin-loaded nanostructured lipid carriers in rat model of Alzheimer's disease:preparation, in vitro and in vivo evaluation. Int J Nanomed. 2023: 1631- 1658.

[145] DeMaagd G , Philip A . Parkinson's disease and its management:part 1:disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharmacy and therapeutics. 2015; 40 (8): 504.

[146] Reichmann H . View point:etiology in Parkinson's disease. Dual hit or spreading intoxication. J Neurol Sci. 2011; 310 (1-2): 9- 11.

[147] Agrawal Y , Patil K , Mahajan H , et al. In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach. Drug Deliv. 2022; 29 (1): 1112- 1121.

[148] Dudhipala N , Gorre T . Neuroprotective effect of ropinirole lipid nanoparticles enriched hydrogel for Parkinson's disease:in vitro, ex vivo, pharmacokinetic and pharmacodynamic evaluation. Pharmaceutics. 2020; 12 (5): 448.

[149] Mishra N , Sharma S , Deshmukh R , Kumar A , Sharma R . Development and characterization of nasal delivery of selegiline hydrochloride loaded nanolipid carriers for the management of Parkinson's disease. Cent Nerv Syst Agents Med Chem. 2019; 19 (1): 46- 56.

[150] Salunkhe SS , Bhatia NM , Bhatia MS . Implications of formulation design on lipidbased nanostructured carrier system for drug delivery to brain. Drug Deliv. 2016; 23 (4): 1306- 1316.

[151] Sun M , Nie S , Pan X , Zhang R , Fan Z , Wang S . Quercetin-nanostructured lipid carriers:characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces. 2014; 113: 15- 24.

[152] Jemal A , Bray F , Center MM , Ferlay J , Ward E , Forman D . Global cancer statistics. Ca-Cancer J Clin. 2011; 61 (2): 69- 90.

[153] Poonia N , Narang JK , Lather V , et al. Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting:systematic development, characterization and pharmacokinetic evaluation. Colloids Surf B Biointerfaces. 2019; 181: 756- 766.

[154] Aghazadeh T , Bakhtiari N , Rad IA , Ramezani F . Formulation of kaempferol in nanostructured lipid carriers (NLCs):a delivery platform to sensitization of MDAMB468 breast cancer cells to paclitaxel. Biointerface Res. Appl. Chem. 2021; 11 (6): 14591- 14601.

[155] Di H , Wu H , Gao Y , Li W , Zou D , Dong C . Doxorubicin-and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug Dev Ind Pharm. 2016; 42 (12): 2038- 2043.

[156] Ng WK , Saiful Yazan L , Yap LH , Wan Nor Hafiza WAG , How CW , Abdullah R . Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). BioMed Res Int. 2015; 2015.

[157] Sabale V , Jiwankar M . Nanostructured lipid carriers:an approach to oral delivery of drugs. Res J Pharm Technol. 2024; 17 (5): 2427- 2430.

[158] Patel HP , Vasandia AV , Jha R , et al. Intranasal delivery of doxepin:enhancing brain targeting efficiency utilizing nanostructured lipid carriers for a biopharmaceutics drug disposition classification system class-I drug. Pharmaceut Dev Technol. 2024; 29 (6): 639- 647.

[159] Shimon Makkar , Abhishek Sharma , Charul Rathore , Gaurav Joshi , Suveksha Rawat . Recent update on applications of nanostructured lipid and solid lipid nanocarriers carriers in drug delivery systems:a narrative review. Current Nanomed. 2024.

RIGHTS & PERMISSIONS

The Authors. Publishing services by Elsevier B.V. on behalf of Higher Education Press and KeAi Communications Co. Ltd.